Literature DB >> 9753486

Differential lamina propria cell migration via basement membrane pores of inflammatory bowel disease mucosa.

M E McAlindon1, T Gray, A Galvin, H F Sewell, D K Podolsky, Y R Mahida.   

Abstract

BACKGROUND & AIMS: In active inflammatory bowel disease (IBD), the intestinal mucosa is infiltrated by polymorphonuclear cells (PMNs), lymphocytes, and monocytes from the systemic circulation. Using an ex vivo model, we have investigated luminally directed migration of cells out of the lamina propria.
METHODS: Fresh untreated and deepithelialized mucosal samples were studied by electron microscopy. Cells migrating out of the lamina propria were investigated by immunohistochemistry and fluorescence-activated cell sorter analysis.
RESULTS: In intact IBD mucosal samples, tunnels containing cells were prominent in the lamina propria matrix, and PMNs, but not other cell types, were prominent in the epithelium. In deepithelialized mucosal samples, the basement membrane was either destroyed or contained numerous large pores. During culture of deepithelialized mucosal samples, many cells (3.3 [+/-0.8] x 10(5) . g tissue-1 . h-1) migrated out of the lamina propria via basement membrane pores. PMNs and eosinophils were prominent during the first 3 hours of culture, but T cells predominated thereafter. Macrophages also migrated, but B cells were the minority population (<2%) at all times.
CONCLUSIONS: In active IBD mucosa with an intact epithelium, luminally directed migration of lamina propria cells is restricted mainly to PMNs. After loss of the epithelium, other cell types also migrate into the lumen via numerous, large, basement membrane pores.

Entities:  

Mesh:

Year:  1998        PMID: 9753486     DOI: 10.1016/s0016-5085(98)70255-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Histopathological parameters as predictors for the course of Crohn's disease.

Authors:  Frauke Bataille; Frank Klebl; Petra Rümmele; Rainer H Straub; Peter Wild; Jürgen Schölmerich; Ferdinand Hofstädter
Journal:  Virchows Arch       Date:  2003-07-24       Impact factor: 4.064

2.  Neutrophil differentiated HL-60 cells model Mac-1 (CD11b/CD18)-independent neutrophil transepithelial migration.

Authors:  Svetlana O Carrigan; Amy L Weppler; Andrew C Issekutz; Andrew W Stadnyk
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

3.  Basement membrane pores in human bronchial epithelium: a conduit for infiltrating cells?

Authors:  W J Howat; J A Holmes; S T Holgate; P M Lackie
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Investigation of the expression of IL-1beta converting enzyme and apoptosis in normal and inflammatory bowel disease (IBD) mucosal macrophages.

Authors:  M E McAlindon; A Galvin; B McKaig; T Gray; H F Sewell; Y R Mahida
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

5.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  Morphological characterisation of Crohn's disease fistulae.

Authors:  F Bataille; F Klebl; P Rümmele; J Schroeder; S Farkas; P-J Wild; A Fürst; F Hofstädter; J Schölmerich; H Herfarth; G Rogler
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

7.  Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease.

Authors:  Brian C McKaig; Daniel McWilliams; Sue A Watson; Yashwant R Mahida
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

8.  Proteolytic and Opportunistic Breaching of the Basement Membrane Zone by Immune Cells during Tumor Initiation.

Authors:  Maaike C W van den Berg; Lucy MacCarthy-Morrogh; Deborah Carter; Josephine Morris; Isabel Ribeiro Bravo; Yi Feng; Paul Martin
Journal:  Cell Rep       Date:  2019-06-04       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.